The central venous catheter market in Europe is expected to grow at a CAGR of 5.07% from 2023 to 2028 and the regional market size is anticipated to be worth USD 0.5 billion by 2028 from USD 0.39 billion in 2023.
The growing patient population suffering from cardiovascular diseases and cancer across Europe majorly propels the growth of the European central venous catheter market. Europe reports 6 million new cardiovascular cases and 4 million new cancer cases annually. Central venous catheters also known as central lines play a crucial role in delivering medications, blood and fluids to patients through a large vein in the neck, arm, or chest. These catheters are distinct from standard intravenous lines and are used for longer durations, typically placed above the right side of the heart in the superior vena cava. They enable the administration of fluids and facilitate blood sampling for diagnostic purposes. Central venous catheters are particularly valuable in cancer treatment, as chemotherapy can be effectively delivered through these catheters and they are instrumental in addressing malnutrition among cancer patients by providing nutrient-rich fluids.
The growing number of advancements in the manufacturing of central venous catheters contribute to the growth of the European market. Researchers and manufacturers are dedicated to developing products tailored to the requirements of healthcare providers and specialists, driven by the increasing adoption of central venous catheters in surgical procedures. The ongoing research and development, support from healthcare organizations and government investments further promote the growth rate of the European market.
The rising adoption of central venous catheters in surgical procedures, growing number of research and development activities, increasing support from healthcare organizations and growing investments from the governments of European countries in healthcare infrastructure favour the European market growth. Technological advancements in catheter design and functionality, growing geriatric population and increasing demand for effective and efficient drug delivery systems further fuel the growth rate of the European market.
Stringent regulatory requirements for product approval, high cost associated with central venous catheter procedures and risk of complications and infections associated with catheter usage primarily hamper the growth of the European central venous catheter market. Limited awareness among healthcare professionals about the benefits of central venous catheters, challenges related to the maintenance and management of catheters and limited availability of skilled healthcare professionals for catheter insertion and management further inhibit the growth rate of the European market. Product recalls and safety concerns related to certain central venous catheter brands, alternative treatment options such as oral medications or non-invasive therapies and reimbursement limitations and inadequate insurance coverage for catheter-related procedures further limits the growth rate of the European market.
This research report on the Europe central venous catheter market has been segmented and sub-segmented into the following categories.
By Product Type:
By Design:
By End-User:
By Country:
The European region is a potential regional market for central venous catheters and accounted for a notable share of the worldwide market in 2022. The European regional market is also predicted to witness a healthy CAGR during the forecast period owing to the increasing number of advancements in surgical technologies, growing healthcare expenditure, an increasing number of initiatives and awareness campaigns by the governments of European countries. Germany is a promising regional market for central venous catheters in the European region and is estimated to hold the leading share of the European market during the forecast period. The presence of a large geriatric population, prominent market players, and rapid adoption of catheters in various healthcare settings fuels the German market growth. The UK is predicted to register a healthy CAGR during the forecast period owing to the manufacturing capabilities and increasing number of mergers and partnerships between the market participants. Cost-effective catheters and their use in enhancing treatment and recovery for chronic diseases contribute to the UK market expansion.
KEY MARKET PLAYERS:
Becton, Dickinson and Company, Teleflex Incorporated, B. Braun Melsungen AG, Edwards Lifesciences Corporation and Vygon SA are some of the prominent companies in the European central venous catheters market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region